Financial Report: Catalent

Catalent
3Q Revenues: $627.9 million (+18%)
3Q Earnings: $19.0 million (-27%)
YTD Revenues: $1.8 billion (+22%)
YTD Earnings: $0.9 million (earnings were $48.0 million YTD17)
Comments: Softgel Technologies segment sales were $228.5 million in the quarter, up 9% primarily attributable to the February 2017 Accucaps acquisition. Drug Delivery Solutions revenue was $313.6 million, up 34% primarily attributable to the Cook Pharmica acquisition which contributed 26 percentage points. Excluding the impact of the acquisition, revenue increased 3% driven by biologics offerings and improved capacity utilization for products utilizing our blow-fill-seal technology platform, partially offset by a decrease in product participation revenue and lower volumes related to the analytical development services platform. Clinical Supply Services revenue was $104.4 million in the quarter, up 7%. Growth was due to higher volume related to storage and distribution services, partially offset by volume declines related to manufacturing and packaging services, as well as lower comparator sourcing volume.